Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • liver disease

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

    Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

    Growth driven by increased sales in diabetes and obesity markets

    - PMLiVE

    Roche to acquire 89bio in a deal worth up to US$3.5bn

    With the agreement, Roche will gain a treatment for moderate to severe MASH

    - PMLiVE

    Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations

    The transition will help the company meet the rising global demand in the obesity market

    - PMLiVE

    Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

    The rare bleeding disorder affects approximately 800,000 people globally

    - PMLiVE

    Novo Nordisk appoints Maziar Mike Doustdar as president and CEO

    Doustdar has most recently been serving as Novo’s executive vice president of international operations

    - PMLiVE

    Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

    The companies will launch four development programmes for potential small molecule therapies

    - PMLiVE

    GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

    Steatotic liver disease affects approximately 5% of the global population

    - PMLiVE

    Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis

    The drug has already been approved in the US to treat patients with non-cirrhotic MASH

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links